76.90
0.18%
-0.14
After Hours:
76.68
-0.22
-0.29%
Overview
News
Price History
Option Chain
Why AZN Down?
Discussions
Forecast
Stock Split
Dividend History
Astrazeneca PLC stock is currently priced at $76.90, with a 24-hour trading volume of 2.78M.
It has seen a -0.18% decreased in the last 24 hours and a +12.21% rose in the past month.
The chart indicates a potential bearish trend, as the stock is below the $76.95 pivot point. If it approaches the $76.67 support level, significant changes may occur.
Previous Close:
$77.04
Open:
$76.87
24h Volume:
2.78M
Market Cap:
$238.43B
Revenue:
$47.61B
Net Income/Loss:
$6.33B
P/E Ratio:
38.84
EPS:
1.98
Net Cash Flow:
$5.79B
1W Performance:
-0.36%
1M Performance:
+12.21%
6M Performance:
+19.91%
1Y Performance:
+2.95%
Astrazeneca PLC Stock (AZN) Company Profile
Name
Astrazeneca PLC
Sector
Industry
Phone
44 20 3749 5000
Address
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge
Astrazeneca PLC Stock (AZN) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Apr-16-24 | Upgrade | Deutsche Bank | Sell → Hold |
Feb-08-24 | Downgrade | Deutsche Bank | Hold → Sell |
Jan-23-24 | Initiated | Morgan Stanley | Overweight |
Jan-16-24 | Resumed | UBS | Sell |
Jan-03-24 | Downgrade | Jefferies | Buy → Hold |
Dec-18-23 | Initiated | HSBC Securities | Buy |
Sep-25-23 | Upgrade | Jefferies | Hold → Buy |
Jul-14-23 | Initiated | HSBC Securities | Buy |
Jul-12-23 | Upgrade | UBS | Neutral → Buy |
Jul-05-23 | Downgrade | Deutsche Bank | Buy → Hold |
Apr-11-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Jan-05-23 | Initiated | BMO Capital Markets | Outperform |
Sep-15-22 | Downgrade | Credit Suisse | Outperform → Neutral |
Sep-07-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Aug-29-22 | Upgrade | Argus | Hold → Buy |
Jun-14-22 | Downgrade | UBS | Buy → Neutral |
Feb-11-22 | Upgrade | DZ Bank | Sell → Hold |
Dec-07-21 | Downgrade | Jefferies | Buy → Hold |
Aug-12-21 | Resumed | JP Morgan | Overweight |
Apr-12-21 | Downgrade | Argus | Buy → Hold |
Mar-16-21 | Upgrade | Jefferies | Hold → Buy |
Feb-25-21 | Upgrade | UBS | Neutral → Buy |
Jan-15-21 | Initiated | Deutsche Bank | Buy |
Dec-07-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Nov-30-20 | Upgrade | UBS | Sell → Neutral |
Nov-11-20 | Upgrade | HSBC Securities | Reduce → Hold |
Sep-29-20 | Initiated | Berenberg | Buy |
Nov-22-19 | Initiated | SVB Leerink | Outperform |
Oct-25-19 | Upgrade | Liberum | Hold → Buy |
Apr-02-19 | Downgrade | UBS | Neutral → Sell |
Feb-05-19 | Initiated | Exane BNP Paribas | Outperform |
Jan-25-19 | Upgrade | Shore Capital | Hold → Buy |
Dec-11-18 | Resumed | Jefferies | Hold |
Oct-09-18 | Initiated | Guggenheim | Buy |
Aug-16-18 | Downgrade | Jefferies | Buy → Hold |
Mar-19-18 | Upgrade | Jefferies | Hold → Buy |
Feb-06-18 | Reiterated | Leerink Partners | Mkt Perform |
Feb-05-18 | Reiterated | Bernstein | Outperform |
Jan-18-18 | Reiterated | Leerink Partners | Mkt Perform |
Dec-29-17 | Upgrade | JP Morgan | Neutral → Overweight |
Oct-16-17 | Upgrade | Credit Suisse | Neutral → Outperform |
Sep-25-17 | Upgrade | Exane BNP Paribas | Neutral → Outperform |
Sep-22-17 | Upgrade | Bernstein | Mkt Perform → Outperform |
View All
Astrazeneca PLC Stock (AZN) Latest News
Britain expects verdict on Pfizer's COVID-19 vaccine before AstraZeneca's - Times - Yahoo News UK
Yahoo News UK
AstraZeneca Sharpens Focus on Innovation - TipRanks.com - TipRanks
TipRanks
Pfizer Unit Wins $107.5M Patent Verdict Against AstraZeneca - Law360
Law360
Pfizer wins $107.5 million from AstraZeneca in US cancer drug patent trial - Reuters
Reuters
Why AstraZeneca (AZN) Might Surprise This Earnings Season - Yahoo Lifestyle UK
Yahoo Lifestyle UK
AstraZeneca PLC ADR falls Friday, underperforms market - MarketWatch
MarketWatch
Astrazeneca PLC Stock (AZN) Financials Data
Astrazeneca PLC (AZN) Revenue 2024
AZN reported a revenue (TTM) of $47.61 billion for the quarter ending March 31, 2024, a +8.60% rise year-over-year.
Astrazeneca PLC (AZN) Net Income 2024
AZN net income (TTM) was $6.33 billion for the quarter ending March 31, 2024, a +34.59% increase year-over-year.
Astrazeneca PLC (AZN) Cash Flow 2024
AZN recorded a free cash flow (TTM) of $5.79 billion for the quarter ending March 31, 2024, a -4.08% decrease year-over-year.
Astrazeneca PLC (AZN) Earnings per Share 2024
AZN earnings per share (TTM) was $2.035 for the quarter ending March 31, 2024, a +34.77% growth year-over-year.
About Astrazeneca PLC
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases. The company's marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Eklira Genuair/Tudorza Pressair, Fasenra, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, Symbicort Turbuhaler, and Tudorza Pressair for respiratory diseases; Fluenz FluMist/Tetra Quadrivalen and Synagis3 for infection diseases; Movantik/Moventig, Seroquel IR, Seroquel XR, and Vimovo4 for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases. The company serves primary care and specialty care physicians through distributors and local representative offices. AstraZeneca PLC has a strategic partnership with Bicycle Therapeutics; and with Biothera Pharmaceuticals, Inc. to evaluate cancer related drugs, as well as has a collaboration agreement with Innate Pharma S.A. for oncology development. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC has clinical collaboration with Immunomedics, Inc. for the development of Imfinzi(R) and sacituzumab govitecan combination therapy, to include second-line metastatic non-small cell lung cancer. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom.
Cap:
|
Volume (24h):